Wednesday, February 08, 2023

News Destination For The Global Indian Community

News Destination For The Global Indian Community

HEALTH
LifeMag
intranasal Covid vaccine to be launched in India

Intranasal Covid vaccine to be launched in India

Indian Vaccine maker Bharat Biotech's intranasal vaccine for Covid-19, the first in the world, is scheduled to be introduced in the country as a booster dose shortly. The vaccine, iNCOVACC (BBV154), is now available on CoWin, and priced at Rs 800 for private markets and Rs 325 for supplies to the Centre and state governments, the Hyderabad-based company said.

Recently, Bharat Biotech received approval from the Central Drugs Standard Control Organization (CDSCO) for the use of heterologous booster doses of iNCOVACC. It is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion-stabilised SARS-CoV-2 spike protein.

This intranasal vaccine candidate was evaluated in phases I, II III clinical trials with successful results, the company said. iNCOVACC has been specifically formulated to allow intranasal delivery through nasal drops. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries, it added.

Intranasal Covid vaccine to be launched in India

intranasal Covid vaccine to be launched in India

Indian Vaccine maker Bharat Biotech's intranasal vaccine for Covid-19, the first in the world, is scheduled to be introduced in the country as a booster dose shortly. The vaccine, iNCOVACC (BBV154), is now available on CoWin, and priced at Rs 800 for private markets and Rs 325 for supplies to the Centre and state governments, the Hyderabad-based company said.

Recently, Bharat Biotech received approval from the Central Drugs Standard Control Organization (CDSCO) for the use of heterologous booster doses of iNCOVACC. It is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion-stabilised SARS-CoV-2 spike protein.

This intranasal vaccine candidate was evaluated in phases I, II III clinical trials with successful results, the company said. iNCOVACC has been specifically formulated to allow intranasal delivery through nasal drops. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries, it added.

Leave a comment

Comments (0)

Related Articles

Opinion Express TV

Shapoorji Pallonji

GOVNEXT INDIA FOUNDATION

CAMBIUM NETWORKS TECHNOLOGY

Opinion Express Magazine

TRANS GLOBE ADVISORS